Table 3.

Change from baseline in glycosylated hemoglobin and fasting plasma glucose between treatment groups

Efficacy outcome	Week	Treatment	n	Mean ± SD	LS mean difference of change from baseline saroglitazar vs. pioglitazone
					Estimate	Standard error	95% confidence interval	p-values
HbA1C (%)	week 12	Saroglitazar 2 mg	192	8.77 ± 1.86	0.40	0.17	(0.08, 0.73)	0.0156
		Saroglitazar 4 mg	206	8.51 ± 1.57	0.18	0.15	(− 0.12, 0.48)	0.2368
	week 24	Saroglitazar 2 mg	192	8.38 ± 1.66	0.23	0.16	(− 0.08, 0.54)	0.1536
		Saroglitazar 4 mg	206	8.25 ± 1.61	0.10	0.15	(− 0.19, 0.40)	0.4924
	week 56	Saroglitazar 2 mg	192	8.42 ± 1.84	0.31	0.17	(− 0.03, 0.65)	0.0698
		Saroglitazar 4 mg	206	8.23 ± 1.73	0.15	0.16	(− 0.18, 0.47)	0.3742
FPG (mg/dL)	week 12	Saroglitazar 2 mg	192	163.15 ± 70.14	13.31	6.26	(1.00, 25.61)	0.0341
		Saroglitazar 4 mg	206	156.18 ± 60.92	6.55	5.72	(− 4.69, 17.79)	0.2524
	week 24	Saroglitazar 2 mg	192	165.98 ± 67.44	13.28	6.24	(1.01, 25.54)	0.0340
		Saroglitazar 4 mg	206	157.32 ± 67.98	4.85	6.23	(− 7.39, 17.09)	0.4363
	week 56	Saroglitazar 2 mg	192	148.95 ± 52.41	4.76	5.18	(− 5.42, 14.93)	0.3587
		Saroglitazar 4 mg	206	148.22 ± 60.25	4.18	5.47	(− 6.57, 14.94)	0.4447

Estimate, standard error, p-values and 95% CI are calculated based on ANCOVA (Analysis of Covariance)

n number of subjects in the specified category, LS least square